IL17A and rheumatoid arthritis: While IL-17-dependent pathologies are seen in primary non-responders to other treatments such as anti-TNF therapy for rheumatoid arthritis (78), more commonly it is found that IL-17 synergistically promotes inflammation in several inflammatory diseases rather than acting as the primary driver of inflammation.